Objective
A critical need in cancer care is the possibility to monitor tumour progression, through non-invasive techniques, to recognize relapses and/or metastases at a very early stage. The measurement of tumour biomarkers circulating into the bloodstream is a feasible way, as it can give indications also on patients’ response to therapeutic treatments, thus enabling the oncologist to pursue a precision-medicine strategy. In patients affected by breast and colon cancer, most serum biomarkers employed in the clinical practice have poor specificity and sensitivity to be used as monitoring tool of the cancer progression. Oncoxx Biotech has collected strong experimental data demonstrating that the transmembrane receptor Trop-2 drives progression of several tumour types. It has also been shown that Trop-2 is a determinant of breast cancer survival, and it is released in the bloodstream in patients with breast and colorectal cancer. In this respect, the results achieved in a preliminary clinical study have shown that all higher-than-baseline levels of circulating Trop-2 identify breast cancers with 100% specificity and 80% sensitivity and colon cancer with 100% of specificity and 74% of sensitivity. Therefore, scope of the ThruBlood project is to validate Trop-2 as a serum biomarker for monitoring disease-course in patients with breast and colon cancer. During Phase 1 we will: 1) assess the scientific feasibility of the proposed biomarker by extending the population of serum samples to analyse; 2) design the Clinical Validation Study to pursue in Phase2; 3) validate a standardized procedure for accurate measurement of the serum Trop-2 levels using a proprietary device (ICONA, patented by the applicant) with aim of providing high-throughput procedures for serum biomarker detection; 4) analyse and validate the business opportunity represented by the introduction of the ThruBlood assay in the current procedure adopted for surveillance of cancer diagnosed and treated patients.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences basic medicine pharmacology and pharmacy drug discovery
- medical and health sciences clinical medicine surgery
- medical and health sciences clinical medicine oncology breast cancer
- medical and health sciences clinical medicine oncology colorectal cancer
- medical and health sciences health sciences personalized medicine
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.3.1.3. - Treating and managing disease
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
SME-1 - SME instrument phase 1
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-SMEInst-2014-2015
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
66034 LANCIANO
Italy
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.